You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
药明康德(02359.HK):药明基金一期拟斥2100万美元认购D3 Bio的A-1系列股份
格隆汇 11-17 22:46

格隆汇 11 月 17日丨药明康德(02359.HK)宣布,于2020年11月17日,药明基金一期等投资者与D3 Bio签署购股协议,据此,药明基金一期同意购买而D3 Bio同意发行及出售2100万股A-1系列股份(占D3 Bio第二次最终交割完成时全面摊薄及转换后已发行股本约16.67%),总对价为2100万美元。包括Hodge Lake、Bright Angel及药明人民币基金在内的合共七名其他投资者亦参与D3 Bio的A系列投资,且为购股协议的订约方。

据悉,D3 Bio是一家全球性生物技术公司,专注于开发及商业化颠覆性精准药物,以改善或替代未能或未能完全满足大量患者需求的现有肿瘤学及免疫学标准护理疗法。D3 Bio与各地的世界一流伙伴合作,通过开发至发现再到开发的渐进迭代循环,将医疗保健领域的深刻临床及市场见解与颠覆性的科技发展相结合。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account